Coherus Oncology, Inc. reports commercial-stage oncology developments centered on LOQTORZI® (toripalimab-tpzi), an approved next-generation PD-1 inhibitor for recurrent or metastatic nasopharyngeal carcinoma. Company updates also cover its antibody immunotherapy pipeline, including tagmokitug, an anti-CCR8 cytolytic antibody, and casdozokitug, an IL-27 antagonistic antibody, across solid-tumor programs such as liver, prostate, head and neck, colorectal, gastric and esophageal cancers.
Recurring news includes financial results, LOQTORZI revenue commentary, clinical-development updates, strategic partnerships, investor-conference presentations, public common-stock offerings, debt reduction and other capital-structure actions tied to the company's transition from biosimilars to innovative oncology.
Coherus Oncology (Nasdaq: CHRS) will release its full year and fourth quarter 2025 financial results after market close on Monday, March 9, 2026. A management conference call and webcast will begin at 4:30 p.m. ET the same day, with a replay posted on the company investor website.
Investors can pre-register for dial-in details and PIN, and the press release and related materials will be available on the Coherus investor site before the call.
Coherus Oncology (NASDAQ: CHRS) said senior management will present at two investor conferences in March 2026 with webcasts and replays available on the company investor events calendar.
Presentations: TD Cowen Healthcare Conference on March 4, 2026 at 11:50 AM ET and Citizens Life Sciences Conference on March 10, 2026 at 2:50 PM ET. Replays will be posted for approximately 90 days.
Coherus Oncology (NASDAQ: CHRS) closed an underwritten public offering of 28,600,000 common shares at $1.75 per share on Feb 17, 2026, generating approximately $50.1 million gross proceeds before fees.
The company granted underwriters a 30-day option to purchase up to 4,290,000 additional shares for over-allotments. Proceeds will support commercialization of LOQTORZI, continued clinical programs, working capital and general corporate purposes.
Coherus Oncology (NASDAQ: CHRS) priced an underwritten public offering of 28,600,000 common shares at $1.75 per share, raising approximately $50.1 million in gross proceeds. The company granted a 30-day option for an additional 4,290,000 shares and expects closing on or about February 17, 2026.
Net proceeds are intended to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development, and for working capital and general corporate purposes.
Coherus Oncology (NASDAQ: CHRS) announced a proposed underwritten public offering of its common stock on Feb 12, 2026.
Key points: Coherus will offer shares from its effective Form S-3 shelf (File No. 333-291520, filed Nov 13, 2025); underwriters have a 30-day option for up to 15% additional shares. Net proceeds are targeted to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development, and for working capital and general corporate purposes. The Offering is subject to market conditions and may not be completed as proposed.
Coherus Oncology (NASDAQ: CHRS) said senior management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30 a.m. PT.
The presentation and Q&A will stream via webcast and a link will be posted on the company's Investor Events Calendar at https://investors.coherus.com/events-presentations. The webcast replay will be available through February 13, 2026.
Coherus Oncology (NASDAQ: CHRS) announced publication in Molecular Cancer Therapeutics describing preclinical and first-in-human biomarker data for investigational anti-CCR8 antibody tagmokitug (CHS-114).
Key findings: picomolar binding affinity, no off-target binding, selective depletion of CCR8+ regulatory T cells, high prevalence and density of CCR8 across many solid tumors, tumor regression in mouse models with enhanced activity when combined with anti-PD-1, and translational proof-of-mechanism showing selective CCR8+ Treg reductions in patients.
The publication supports ongoing clinical development of tagmokitug in combination with toripalimab across multiple solid tumor settings.
Coherus (NASDAQ: CHRS) reported six-year follow-up from the Phase 3 JUPITER-02 trial showing LOQTORZI (toripalimab-tpzi) plus gemcitabine and cisplatin achieved a median overall survival of 64.8 months vs 33.7 months for chemotherapy alone (31-month improvement; HR 0.62; 95% CI 0.45–0.85).
Results presented at ESMO Asia 2025 reinforce LOQTORZI plus chemotherapy as a first-line option for recurrent or metastatic nasopharyngeal carcinoma and summarize key safety findings including immune-mediated adverse events.
Coherus Oncology (NASDAQ: CHRS) reported multiomic biomarker data for CHS-114 from the Phase 1b dose expansion and safety arms in recurrent/metastatic HNSCC on Nov 7, 2025.
Key findings: CHS-114 selectively depleted intratumoral CCR8+ Tregs by 74% and reduced total FOXP3+ Tregs by 43%, while increasing intratumoral CD8+ T cells by 73% and raising the CD8+/CCR8+ Treg ratio 12-fold. Peripheral blood showed sustained CD8+ activation and proliferation with combination dosing. Safety was described as manageable; a partial response was observed in one refractory HNSCC patient. Data were presented at SITC 2025 (abstract #640) with the presentation on Nov 8, 2025.
Coherus Oncology (NASDAQ: CHRS) reported Q3 2025 results and a business update on Nov 6, 2025. LOQTORZI net revenue was $11.2M in Q3, up 12% QoQ and 92% YoY; total net revenue from continuing operations was $11.6M for the quarter. Cash, cash equivalents and marketable securities were $191.7M as of Sept 30, 2025. R&D spending rose to $27.3M in Q3 while SG&A declined to $24.9M. Net loss from continuing operations was $44.5M, or $(0.38) per share, with non-GAAP net loss of $38.9M. Pipeline progress includes expansion of CHS-114 into colorectal cancer and multiple 2026 readouts for CHS-114 and casdozokitug.